[Anti-microbial resistance in intensive care units in Bogotá, Colombia, 2001-2003].
OBJECTIVE
Determining the frequency of antimicrobial resistance amongst bacterial isolates obtained from patients in Intensive Care Units (ICU).


METHODS
Study data relating to 2001 to 2003 regarding microbiological isolates was obtained from a laboratory network for the ICUs of 14 third-level hospitals in Bogotá belonging to the Bogotá Bacterial Resistance Control Group (BBRCG). 27,301 isolates were obtained and their susceptibility profiles were analysed using WHONET 5.3.


RESULTS
Staphylococcus aureus, Escherichia coli, coagulase negative Staphylococci (CNS), Pseudomonas aeruginosa y Klebsiella pneumoniae were the most commonly found microorganisms. Oxacillin-resistance rate ranged from 61% at 63% during 2001 to 2003 amongst S. aureus isolates and 78% to 83% amongst coagulase negative Staphylococci (CNS). E. coli resistance to third generation cephalosporines was found to be about 10% and over 20% to ciprofloxacin. K. pneumoniae isolates' resistance to third-generation cephalosporines was found to be more than 30% in 2001. P. aeruginosa resistance to all but a few antibiotics was found to be over 30% and multirresistance frequency was found to be 16% to 24%.


CONCLUSIONS
The antimicrobial resistance rates found in the ICU of hospitals in Bogotá were higher than those reported in surveillance studies in the USA, Europe or other Latin-American cities.
Alvarez
Carlos
C
Unidad de Infectología, Hospital Universitario San Ignacio, Facultad de Medicina, Universidad Nacional de Colombia. caalvarezmo@unal.edu.co
Cortes
Jorge
J
Arango
Alvaro
A
Correa
Constanza
C
Leal
Aura
A
D000293:Adolescent; D000328:Adult; D001424:Bacterial Infections / Q000453:epidemiology* / Q000382:microbiology; D002176:Candida albicans / Q000187:drug effects; D018550:Cephalosporin Resistance; D002648:Child; D002675:Child, Preschool; D003105:Colombia / Q000453:epidemiology; D003325:Coronary Care Units / Q000706:statistics & numerical data; D003428:Cross Infection / Q000453:epidemiology* / Q000382:microbiology; D024881:Drug Resistance, Bacterial; D025141:Drug Resistance, Fungal; D024901:Drug Resistance, Multiple, Bacterial; D005060:Europe / Q000453:epidemiology; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007362:Intensive Care Units / Q000706:statistics & numerical data*; D007363:Intensive Care Units, Neonatal / Q000706:statistics & numerical data; D015278:Intensive Care Units, Pediatric / Q000706:statistics & numerical data; D007843:Latin America / Q000453:epidemiology; D014481:United States / Q000453:epidemiology; D014504:Urban Health; D020713:Vancomycin Resistance